Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1

Kidney International

Volumn 66, Issue 3, 2004, Pages 990-1000

  Luijerink, Marjanka C ^b   Van Beurden, Ellen A C M ^b   Malingré, Helga E M ^b   Jacobs, Saskia M M ^b   Grompe, Markus ^b   Klomp, Leo W J ^b   Berger, Ruud ^b   Van Den Berg, Inge E T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

Acquired resistance to cell death; Apoptotic cell death; Caspase 3; Caspase 9; Hereditary tyrosinemia type 1; Kidney damage

Indexed keywords

CASPASE 3; CASPASE 9; DNA FRAGMENT; FUMARYLACETOACETASE; HOMOGENTISIC ACID; NITISINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; HISTOPATHOLOGY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KNOCKOUT MOUSE; MOUSE; NICK END LABELING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TYROSINEMIA;

EID: 4344611693     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00788.x     Document Type: Article

References (32)

1. MITCHELL GA, GROMPE M, LAMBERT M, TANGUAY RM: Hypertyrosinemia, in The Metabolic and Molecular Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, 8th edition, New York, McGraw-Hill, 2001, pp 1777-1805
2. KVITTINGEN EA: Hereditary tyrosinemia type I - an overview. Scand J Clin Lab Invest 184(Suppl):27-34, 1986
3. VAN SPRONSEN FJ, THOMASSE Y, SMIT GP, et al: Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment. Hepatology 20:1187-1191, 1994
4. LAINE J, SALO MK, KROGERUS L, et al: The nephropathy of type I tyrosinemia after liver transplantation. Pediatr Res 37:640-645, 1995
5. RUSSO P, O'REGAN S: Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet 47:317-324, 1990
6. LINDSTEDT S, HOLME E, LOCK EA, et al: Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813-817, 1992
7. GROMPE M, AL DHALIMY M, FINEGOLD M, et al: Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7:2298-2307, 1993
8. GROMPE M, LINDSTEDT S, AL DHALIMY M, et al: Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 10:453-460, 1995
9. DIETER MZ, FRESHWATER SL, MILLER ML, et al: Pharmacological rescue of the 14CoS/14CoS mouse: Hepatocyte apoptosis is likely caused by endogenous oxidative stress. Free Radic Biol Med 35:351-367, 2003
10. KELSEY G, RUPPERT S, BEERMANN F, et al: Rescue of mice homozygous for lethal albino deletions: Implications for an animal model for the human liver disease tyrosinemia type 1. Genes Dev 7:2285-2297, 1993
11. RUPPERT S, KELSEY G, SCHEDL A, et al: Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev 6:1430-1443, 1992
12. JORQUERA R, TANGUAY RM: Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J 13:2284-2298, 1999
13. ENDO F, KUBO S, AWATA H, et al: Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem 272:24426-24432, 1997
14. KUBO S, SUN M, MIYAHARA M, et al: Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA 95:9552-9557, 1998
15. SUN MS, HATTORI S, KUBO S, et al: A mouse model of renal tubular injury of tyrosinemia type 1: Development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice. J Am Soc Nephrol 11:291-300, 2000
16. VOGEL A, VAN DEN BERG I, AL DHALIMY M, et al: Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology 39:433-443, 2004
17. JAKOBS C, DORLAND L, WIKKERINK B, et al: Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: An accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I. Clin Chim Acta 171:223-231, 1988
18. GROMPE M, JONES SN, LOULSEGED H, CASKEY CT: Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice. Hum Gene Ther 3:35-44, 1992
19. PONDER KP, GUPTA S, LELAND F, et al: Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci USA 88:1217-1221, 1991
20. LUIJERINK MC, JACOBS SM, VAN BEURDEN EA, et al: Extensive changes in liver gene expression induced by hereditary tyrosine-mia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione (NTBC). J Hepatol 39:901-909, 2003
21. DONG Z, SAIKUMAR P, WEINBERG JM, VENKATACHALAM MA: Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol 151:1205-1213, 1997
22. KOK YJ, SWE M, SIT KH: Necrosis has orderly DNA fragmentations. Biochem Biophys Res Commun 294:934-939, 2002
23. TSUKADA T, WATANABE M, YAMASHIMA T: Implications of CAD and DNase II in ischemic neuronal necrosis specific for the primate hippocampus. J Neurochem 79:1196-1206, 2001
24. SLEE EA, HARTE MT, KLUCK RM, et al: Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281-292, 1999
25. EDELSTEIN CL, SHI Y, SCHRIER RW: Role of caspases in hypoxia-induced necrosis of rat renal proximal tubules. J Am Soc Nephrol 10:1940-1949, 1999
26. LOCK EA, GASKIN P, ELLIS MK, et al: Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology 144:179-187, 2000
27. MIYAJI T, KATO A, YASUDA H, et al: Role of the increase in p21 in cisplatin-induced acute renal failure in rats. J Am Soc Nephrol 12:900-908, 2001
28. SANO K, FUJIGAKI Y, MIYAJI T, et al: Role of apoptosis in uranyl acetate-induced acute renal failure and acquired resistance to uranyl acetate. Kidney Int 57:1560-1570, 2000
29. JORQUERA R, TANGUAY RM: The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 232:42-48, 1997
30. NEBERT DW, ROE AL, DIETER MZ, et al: Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 59:65-85, 2000
31. HOLME E, LINDSTEDT S: Nontransplant treatment of tyrosinemia. Clin Liver Dis 4:805-814, 2000
32. HOLME E, LINDSTEDT S: Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21:507-517, 1998